Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accumulated Expenses for 3 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 56.68% to $7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 million, a 56.68% increase, with the full-year FY2025 number at $7.6 million, up 56.68% from a year prior.
  • Accumulated Expenses was $7.6 million for Q4 2025 at Artiva Biotherapeutics, up from $5.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.6 million in Q4 2025 to a low of $4.0 million in Q4 2023.
  • A 3-year average of $5.6 million and a median of $5.6 million in 2025 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 56.68% in 2025; the steepest drop was 17.35% in 2025.
  • Artiva Biotherapeutics' Accumulated Expenses stood at $4.0 million in 2023, then increased by 19.37% to $4.8 million in 2024, then soared by 56.68% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Accumulated Expenses are $7.6 million (Q4 2025), $5.6 million (Q3 2025), and $5.8 million (Q2 2025).